US › Healthcare

Sonoma Pharmaceuticals Inc (SNOA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.20+7.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$5.6M
Revenue YoY
+48.1%
Net profit
$-581,000
Profit YoY
+25.1%
EPS
$-0.15
Net margin
-10.4%

Key statistics

Market cap
$5.3M
Forward P/E
46.1
P/B
1.72
Book value
$1.72
EPS (TTM)
$-1.89
52-week high
$6.92
52-week low
$0.85
50-day MA
$1.16
200-day MA
$2.46
Beta
1.27

Analyst view

Analysts rate Sonoma Pharmaceuticals Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders
0.42%
Institutions
1.43%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.42%
Vanguard Group Inc0.39%
Vanguard Capital Management, LLC0.39%
DRW Securities, LLC0.25%
Mckinley Carter Wealth Services Inc0.23%
Morgan Stanley - Brokerage Accounts0.04%
Citigroup Inc0.03%
Tower Research Capital LLC0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sonoma Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.